IVA - Mergers and acquisitions

Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to €130 million in committed tranches, subject to conditions, plus an additional uncommitted tranche of up to €20 million, to replace its existing EIB loan ahead of maturity and extend its debt maturity profile to 2030Simplifying its capital structure with agreement to repurchase existing warrants issued in favor of the EIB, thereby eliminating 60% of the dilution protected EIB warrants (exercisable into 22.7 million shares), at a 40% discount to intrinsic value, and restructuring the remaining EIB warrants on terms that do not contain dilution protectionPriced an underw

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced an approximately €35.7 million financing. The financing consists of two transactions: (i) a capital increase reserved to specified categories of investors (the "Capital Increase"), for an amount of €30,587,269 million through the issuance of 9,618,638 newly-issued ordinary shares with a nominal value of €0.01 per share (